Purchase this article with an account.
Sonia Dhoot, Howard Guan, Keith Tokuhara; Role of Subconjunctival Bevacizumab in Post-Pterygium Excision Management. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3102.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The exact pathogenesis of pterygium formation is unknown, but previous research has demonstrated that various growth factors, including VEGF, may play a role. The use of VEGF inhibitors bevacizumab and ranibizumab is poorly understood in inhibiting pterygium growth. The objective of this study was to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.
This was a prospective trial. Thirty-one patients with a primary pterygium of at least 2 mm in size and without any previous ocular surgery were included. Seventeen patients received 5mg postoperative bevacizumab on postoperative weeks two and six, while fourteen patients received no bevacizumab. Outcome measures included best corrected visual acuity, intraocular pressure, recurrence, and any sight threatening complications at two weeks, two months, and six months postoperatively.
Six patients were lost to follow-up, four of which were assigned to the bevacizumab group. Of the remaining thirteen patients in the bevacizumab group, four had recurrence of the pterygium (30.7%). Two of the remaining twelve in the control group had a recurrence (16.7%).
Bevacizumab does not improve recurrence rates for pterygia when used as an adjunctive therapy postoperatively. It may even cause increased rates of recurrence, although further studies are needed before arriving at this conclusion.
This PDF is available to Subscribers Only